IPP Bureau

Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth
Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth

By IPP Bureau - June 10, 2022

The Accelerator will develop products and solutions that will support Sanofi’s mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).

Sanofi Dupixent gets USFDA nod for atopic dermatitis
Sanofi Dupixent gets USFDA nod for atopic dermatitis

By IPP Bureau - June 10, 2022

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

India's bio-economy has grown 8 times in the last 8 years: PM Modi
India's bio-economy has grown 8 times in the last 8 years: PM Modi

By IPP Bureau - June 10, 2022

We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”

GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

By IPP Bureau - June 10, 2022

Healthcare is timely and personal – and its delivery should be too

Bayer’s Vividion emerging as significant player in San Diego Biotech hub
Bayer’s Vividion emerging as significant player in San Diego Biotech hub

By IPP Bureau - June 10, 2022

Bayer now present in four of the largest biotechnology hubs in the United States

University of Glasgow opens Mazumdar Shaw Advance Research Centre
University of Glasgow opens Mazumdar Shaw Advance Research Centre

By IPP Bureau - June 10, 2022

The £118 million Mazumdar-Shaw Advanced Research Centre (ARC) will be the creative and collaborative heart of cross-disciplinary research at the University of Glasgow.

National Ayurveda Research Institute for Panchakarma bags NABL Accreditation
National Ayurveda Research Institute for Panchakarma bags NABL Accreditation

By IPP Bureau - June 09, 2022

A big boost to healthcare efforts of Ayush through NARIP, CCRAS

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

By IPP Bureau - June 09, 2022

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.

Krsnaa Diagnostics bags contract in Tripura
Krsnaa Diagnostics bags contract in Tripura

By IPP Bureau - June 08, 2022

The company will provide free Diagnostics Service- X-ray Tele Radiology Services in District Hospitals / Sub-district Hospitals / Community Health Centers in the State of Tripura.

Merck and Ridgeback announce new data for investigational molnupiravir
Merck and Ridgeback announce new data for investigational molnupiravir

By IPP Bureau - June 08, 2022

Based on a post hoc analysis, fewer required respiratory interventions

Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients
Novartis Tafinlar and Mekinist demonstrates unprecedented efficacy in pediatric patients

By IPP Bureau - June 08, 2022

If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer

Eugia Pharma receives USFDA Approval for Leuprolide Acetate Injection
Eugia Pharma receives USFDA Approval for Leuprolide Acetate Injection

By IPP Bureau - June 08, 2022

he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.

ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr
ANG Lifesciences India Q4 FY 22 net profit soars to Rs. 5.28 Cr

By IPP Bureau - June 08, 2022

The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod
Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

By IPP Bureau - June 08, 2022

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis

Tetra Bio-Pharma opens new subsidiary in Australia
Tetra Bio-Pharma opens new subsidiary in Australia

By IPP Bureau - June 08, 2022

The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.

Latest Stories

Interviews

Packaging